Key Takeaways
- Spyre Therapeutics secured Guggenheim’s top biotech designation following encouraging Phase II results for SPY003 in treating ulcerative colitis
- The SKYLINE-UC trial demonstrated 20% clinical remission and 30% endoscopic remission with SPY003
- Baird maintained its Outperform rating with a $116 price objective; Guggenheim established a $130 target
- Shares have surged 442% year-to-date, currently hovering near $90.79
- Critical findings from the expanded SKYLINE Part B combination trial are anticipated in 2027
Spyre Therapeutics (SYRE) shares climbed more than 2% during Wednesday’s session, reaching approximately $90.79, after Guggenheim designated the company as its premier biotech selection based on Phase II clinical trial outcomes for SPY003, its ulcerative colitis therapeutic candidate.
Spyre Therapeutics, Inc., SYRE
The clinical study, designated SKYLINE-UC, assessed SPY003 monotherapy across three treatment groups encompassing 135 total participants. SPY003 represents an extended-duration anti-IL-23 monoclonal antibody.
The findings revealed 20% clinical remission, 30% endoscopic remission, and a negative 10.0 shift in the Robarts Histopathology Index. According to Guggenheim, these outcomes align with other IL-23p19 comparator medications currently available in the marketplace.
Approximately 41% of study participants were classified as advanced therapy-experienced, indicating that a substantial portion had previously attempted and discontinued other treatment options, including JAK inhibitors and IL-12/23 therapies. The safety data proved favorable, with zero drug-related serious adverse events reported and no patient withdrawals due to adverse reactions.
Guggenheim emphasized durability as SPY003’s primary competitive edge, characterizing it as a promising candidate for combination therapy applications beyond monotherapy use alone.
Analyst Perspectives
Baird reaffirmed its Outperform designation on Wednesday, maintaining its $116 price objective. The investment firm characterized the SPY003 outcomes as unsurprising given the well-validated mechanism of action, while describing them as modestly encouraging.
Baird emphasized that the IL-23 inhibitory approach has received validation through other regulatory-approved medications. The firm’s attention has shifted toward future developments: the expanded, placebo-controlled SKYLINE Part B investigation.
Guggenheim confirmed its Buy recommendation with a $130 price objective. Stifel similarly maintained its Buy stance with a $123 target. Mizuho increased its price target to $120, highlighting SPY120’s capacity to deliver robust clinical remission outcomes.
However, not all analysts share this optimism. Wolfe Research reduced SYRE to Peerperform from Outperform, expressing reservations regarding recent data assessment and diminished conviction in forthcoming catalysts.
Future Catalysts
The conclusion of Phase II Part A creates the pathway for Part B, which is currently enrolling study participants. This investigation will examine two dosage levels for each monotherapy alongside three high-dose combination therapy groups, targeting the Ī±4Ī²7, TL1A, and IL-23 pathways simultaneously.
Initial induction findings from Part B are projected for 2027. Baird indicated this timeline represents when the most crucial data supporting the company’s fundamental investment thesis will emerge.
Additionally, a near-term milestone warrants attention. Spyre’s SPY072 SKYWAY-RD results in psoriatic arthritis and axial spondyloarthritis are scheduled for Q4 2026.
On a cautionary note, Spyre recently disclosed that SPY072 in a rheumatoid arthritis substudy failed to achieve its internal benchmark for monotherapy advancement, despite demonstrating statistically significant benefits compared to placebo. This outcome contributed to the Wolfe Research rating reduction.
The Street consensus maintains a strong buy recommendation, with price objectives spanning from $97 to $130. SYRE shares have appreciated 442% year-to-date.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
